The Application of Robotics to Aseptic Environmental Surface Monitoring - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Application of Robotics to Aseptic Environmental Surface Monitoring
This article presents a study of an aseptic environmental monitoring system for surface contamination at critical areas using a robot.


Pharmaceutical Technology



Table V: Wet swab efficiency (manual).
When the wetting agent was changed from distilled water to mixture 0.1%Tween 80 in distilled water, the rate of recovery of M. luteus improved, but complete recovery could not be achieved. Increasing the number of back-and-forth swabbing motions actually resulted in a decrease in recovery rates (see Table IV). A comparison of manual sampling to robotic sampling under the same test conditions showed a lower recovery rate associated with manual swabbing. The recovery efficiency observed with manual swabbing was approximately 20%. Additionally, far more variability in recovery was observed with manual swabbing as compared with robotic swabbing (see Table V).

Discussion


Figure 3
Wet-swab sampling often is avoided in aseptic operations because of concerns about residual moisture that might encourage microbial proliferation. However, the experimental data clearly confirm that moistened swabs are much more effective in terms of contamination recovery. We observed that using surfactant Tween 80 resulted in improved recovery as compared with using plain distilled water. It has been reported that dry, agglomerated microorganisms can strongly adhere to surfaces; therefore, it is logical that moistened swabs, particularly with the addition of a surfactant, can recover this contamination from surfaces. Given the benefits of using moistened swabs, surface monitoring could best be executed just after the completion of an aseptic production operation or in advance of breaking the aseptic condition of the isolator or RABS. As demonstrated in Table IV, even when using the robot for sampling, better efficiency of recovery was observed with B. atrophaeus than with M. luteus.


Figure 4
The most significant difference between these two test organisms is that M. luteus is a vegetative cell and B. atrophaeus is a spore. The sizes are also different. The size of the former is ~0.7–0.8 m, and the latter has a diameter of ~1 2–3 m, although it is unknown to what degree the size of the organism plays a role in recovery efficiency. Consequently, the authors believe the primary considerations in recovery efficiency differences between these two organisms are: spores as compared with vegetative cells, and the agglomeration and adherence to the test coupon. The authors also believe the physical composition of the swab tip may play a role in recovery efficiency. Additional investigation is needed to determine which factors have the greatest influence on recovery rates.


Figure 5
Recovery efficiency was influenced by the time allowed for soaking the swab tip with the wetting agent. Wetting the swab immediately before use does not appear to allow sufficient time for saturation to occur. The authors believe that wetting immediately before use results in a swab that is completely dry before the completion of the swabbing action and therefore less efficient. In this case, the full benefits of wet swabbing are not realized. When the swab tip is allowed to soak overnight before use, however, the swab retains moisture from beginning to end of the swabbing action. The fully saturated swab gave a superior recovery efficiency of microorganisms. Therefore, the degree of wetness of the swabs plays a critical role in recovery efficiency.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here